Blog
RSS FeedPosted by Michael Wonder on 25 Mar 2022
New gene therapy to treat adult patients with multiple myeloma
25 March 2022 - EMA has recommended a conditional marketing authorisation in the European Union for Carvykti (ciltacabtagene autoleucel) for the ...
Posted by Michael Wonder on 25 Mar 2022
ATAGI statement on recommendations on a winter booster dose of COVID-19 vaccine
25 March 2022 - ATAGI recommends an additional booster dose of COVID-19 vaccine to increase vaccine protection before winter for ...
Posted by Michael Wonder on 24 Mar 2022
Leaked TRIPS proposal misguided about improving global COVID-19 vaccination rates
24 March 2022 - The leaked proposal on the waiver on intellectual property rights for COVID-19 vaccines is misguided and ...
Posted by Michael Wonder on 24 Mar 2022
Pressured by patients, FDA reviews ALS drug with modest data
25 March 2022 - The FDA meets next week to review a closely watched drug for ALS, or Lou Gehrig’s ...
Posted by Michael Wonder on 24 Mar 2022
Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis of COVID-19
24 March 2022 - Recommendation based on Phase 3 PROVENT trial showing a significant reduction in the risk of developing ...
Posted by Michael Wonder on 24 Mar 2022
Fresenius Kabi announces FDA approval of SMOFlipid lipid injectable emulsion for paediatric patients requiring parenteral nutrition
24 March 2022 - First and only four-oil lipid injectable emulsion indicated for paediatric parenteral nutrition, including term and preterm neonates. ...
Posted by Michael Wonder on 24 Mar 2022
U.S. FDA approves streamlined process for initiating HIV therapy with Cabenuva (cabotegravir and rilpivirine), the first and only complete long-acting injectable HIV treatment
24 March 2022 - Adults living with HIV now have an option to start injectable regimen without the need for ...
Posted by Michael Wonder on 24 Mar 2022
Pfizer granted FDA breakthrough therapy designation for respiratory syncytial virus vaccine candidate for the prevention of RSV in older adults
24 March 2022 - Pfizer today announced that its respiratory syncytial virus vaccine candidate, PF-06928316 or RSVpreF, received breakthrough therapy ...
Posted by Michael Wonder on 24 Mar 2022
Fennec Pharmaceuticals resubmits new drug application to the U.S. FDA for Pedmark
24 March 2022 - Fennec Pharmaceuticals today announced the resubmission of its new drug application to the U.S. FDA for ...
Posted by Michael Wonder on 24 Mar 2022
Lilly announces complete response letter for sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with non-squamous non-small cell lung cancer
24 March 2022 - Eli Lilly today announced that the U.S. FDA has issued a complete response letter (CRL) for ...
Posted by Michael Wonder on 24 Mar 2022
Moderna finalises strategic partnership with Australian Government
23 March 2022 - On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory ...
Posted by Michael Wonder on 24 Mar 2022
TGA approves new medicine for patients with multiple sclerosis
24 March 2022 - Ponesimod is a sphingosine 1 phosphate receptor 1 modulator. ...
Posted by Michael Wonder on 24 Mar 2022
COVID-19 vaccine weekly safety report (24 March 2022)
24 March 2022 - To 20 March 2022, the TGA has received 485 reports which have been assessed as likely to ...
Posted by Michael Wonder on 23 Mar 2022
Novartis Pluvicto approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer
23 March 2022 - FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA ...
Posted by Michael Wonder on 23 Mar 2022
Moderna has initiated a submission to the FDA for emergency use authorization of mRNA-1273 in children 6 to under 12 years of age
23 March 2022 - Moderna today announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna COVID-19 ...